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The microRNA miR-504 targets TP53 mRNA encoding the p53 tumor
suppressor. miR-504 resides within the fibroblast growth factor 13
(FGF13) gene, which is overexpressed in various cancers. We report
that the FGF13 locus, comprising FGF13 and miR-504, is transcription-
ally repressed by p53, defining an additional negative feedback loop in
the p53 network. Furthermore, we show that FGF13 1A is a nucleolar
protein that represses ribosomal RNA transcription and attenuates pro-
tein synthesis. Importantly, in cancer cells expressing high levels of
FGF13, the depletion of FGF13 elicits increased proteostasis stress, asso-
ciated with the accumulation of reactive oxygen species and apoptosis.
Notably, stepwise neoplastic transformation is accompanied by a gradual
increase in FGF13 expression and increased dependence on FGF13 for
survival (“nononcogene addiction”). Moreover, FGF13 overexpression
enables cells to cope more effectively with the stress elicited by onco-
genic Ras protein.We propose that, in cells inwhich activated oncogenes
drive excessive protein synthesis, FGF13 may favor survival by main-
taining translation rates at a level compatible with the protein quality-
control capacity of the cell. Thus, FGF13may serve as an enabler, allowing
cancer cells to evade proteostasis stress triggered by oncogene activation.
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MicroRNAs (miRNAs) are endogenous noncoding small RNAmolecules (∼22 nucleotides) that regulate gene expression,
particularly at the posttranscriptional level (1). Interestingly, many
miRNAs reside within introns of protein-coding genes and are often
derived from a common primary transcript that also gives rise to the
mature mRNA of their host gene (2). In such cases, the miRNA
biogenesis machinery excises the miRNA precursor (pre-miRNA)
from the intron, eventually converting it into the mature miRNA (3).
miR-504 is an intronic miRNA that targets TP53 mRNA
encoding the p53 tumor suppressor protein (4). miR-504 reduces
p53 mRNA and protein levels and attenuates cellular p53 activity.
p53 serves as a major barrier against cancer, acting primarily as a
transcription factor that regulates cell-fate decisions, including cell
death and cellular senescence, as well as metabolic homeostasis
(5–7). As a consequence of its ability to down-regulate p53, miR-
504 overexpression hampers p53-mediated responses such as cell-
cycle arrest and apoptosis and promotes tumorigenesis (4).
Intriguingly, miR-504 resides within an intron of the fibroblast
growth factor 13 (FGF13) gene (Fig. S1A), a member of the FGF
homologous factors (FHF) family. The proteins comprising this
family (FGF11, FGF12, FGF13, and FGF14, also called FHF3,
FHF1, FHF2, and FHF4, respectively) bear substantial sequence
homology to the core region of the canonical FGF superfamily but
differ from the other FGF proteins in their inability to activate
FGF receptors and thus to function as “real” growth factors (8).
Indeed, the FHFs are intracellular proteins that interact with
various intracellular partners (9, 10).
FGF13 (FHF2), originally cloned from an ovarian cancer cell
line library, is conserved among vertebrates and is normally
expressed most abundantly in the brain (10–13). The FGF13 gene
generates a number of transcripts arising through alternative
splicing and distinct transcription start sites (14) and differing from
each other in their 5′ exons; these isoforms are commonly referred
to as “1S” (FGF13 1A), “1U” (FGF13 1B), “1V,” “1Y,” and “1V+1Y”
(Fig. S1A). These variants are differentially expressed in tissues
and localize to diverse cellular compartments (15), suggesting that
they may possess distinct properties and functions. Interestingly,
FGF13 is overexpressed in several types of cancer (16, 17).
Intronic miRNAs have roles that may complement (18, 19) or
sometimes actually antagonize those of their host genes (20). We
now show that expression of the FGF13 locus, including miR-504,
is negatively regulated by p53. Thus, inhibition of miR-504 ex-
pression by p53 defines a p53-regulatory negative feedback loop.
Importantly, we demonstrate that elevated expression of FGF13 in
cancer-derived cells contributes to their survival. We show that the
FGF13 1A protein is a nucleolar inhibitor of rRNA synthesis, and
its down-regulation in cancer cells induces proteostasis stress, re-
active oxygen species (ROS) accumulation, and cell death. Our
findings are consistent with the conjecture that oncogenic trans-
formation, which pushes the protein synthesis machinery into ex-
cessive activity, induces an increase in misfolded or otherwise
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aberrant proteins. We propose that by attenuating rRNA synthesis,
the up-regulated FGF13 1A mitigates oncogene-associated
proteostasis stress and facilitates the survival of transformed cells.
Thus, although the augmented FGF13 expression in tumors is
unlikely to be a cancer driver, it is not merely a passenger, because
it allows the cancer cells to cope with undesirable side effects of
oncogene activation. As such, FGF13 may be viewed as a cancer
facilitator or “enabler,” representing an example of nononcogene
addiction whose targeted reversal might render tumors more
vulnerable (21).
Results
Expression of the FGF13/miR-504 Unit Is Negatively Regulated by p53.
To determine whether the in vivo expression pattern of miR-504
correlates with that of its FGF13 host gene, we analyzed lung cancer
data from the Cancer Genome Atlas (TCGA) project (22); indeed, a
significant positive correlation was observed (Fig. 1A). Hence, FGF13
and miR-504 probably share a common primary transcript [or tran-
scripts; the FGF13 gene has multiple transcription start sites (Fig.
S1A), giving rise to multiple primary transcripts]. Notably, FGF13
mRNA is significantly elevated in a subset of lung adenocarcinomas,
Fig. 1. Expression of the FGF13/miR-504 unit is up-regulated in lung cancer and is negatively regulated by p53. (A) Dot plot of FGF13mRNA and hsa-miR-504
expression levels in lung adenocarcinoma samples from TCGA. Zero miRNA expression values were ignored. Spearman correlation and P values are indicated.
(B) Box plot of FGF13 mRNA in normal and tumor samples in the TCGA lung adenocarcinoma dataset. The P value was calculated using the rank-sum test.
Outliers were eliminated from box plots. n = number of samples analyzed. (C, Left) qPCR analysis of miR-504 expression normalized to small nucleolar RNA,
C/D box 44 (SNORD44) in H460 cells after transient transfection with p53 siRNA (sip53) or control siRNA (siC) for 48 h. (Right) qPCR analysis of p53 mRNA;
values were normalized to GAPDH. Data are expressed as means ± SD from three independent experiments. *P < 0.05. (D, Upper) FGF13 and p53 mRNA
expression, normalized to GAPDH, of cells treated as in C. Data are expressed as means ± SD from three independent experiments. ***P < 0.001. (Lower) Cell
lysates from the same experiment were subjected to Western blot analysis with the indicated antibodies. GAPDH served as loading control. (E, Upper) FGF13
and p53 mRNA expression, normalized to GAPDH, 48 h after transient transfection of H460 cells with siRNAs targeting p53 (sip53), FGF13 (siFGF13), control
siRNA (siC), or combinations thereof. Data are expressed as means ± SD of duplicates from a representative of three independent experiments. (Lower)
Western blot analysis of the same experiment with antibodies against FGF13 and GAPDH (loading control).
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relative to normal lung tissue (Fig. 1B). Likewise, a fraction of
nonsmall cell lung carcinomas (NSCLC) display FGF13 amplifica-
tion and/or overexpression (Fig. S1B). Moreover, miR-504 is often
up-regulated in EGF receptor-mutant NSCLC (23). These obser-
vations suggest that elevated expression of FGF13 and miR-504 may
endow a subset of lung tumors with a selective advantage.
To explore the relevance of FGF13 overexpression in lung cancer,
we used the human NSCLC cell line H460 expressing abundant
FGF13 and miR-504. H460 cells harbor mutant K-Ras protein and
retain WT p53. Remarkably, siRNA-mediated p53 silencing in-
creased miR-504 (Fig. 1C) and FGF13 mRNA and protein (Fig. 1D
and E), as also confirmed with a different p53 siRNA (Fig. S1C).
Quantitative PCR (qPCR) analysis revealed that H460 cells express
high levels of the 1A isoform, and this expression is up-regulated
upon p53 knockdown (Fig. S1D). Thus, p53 restricts the expression
of its negative regulator miR-504 and its host gene FGF13. The
underlying mechanism might be indirect, because we could not
detect binding of p53 to the FGF13 promoter region in ChIP
assays, nor is such binding suggested by previously published
ChIP-sequencing data.
FGF13 Restricts ROS Accumulation and Promotes Cancer Cell Survival.
FGF13 is overexpressed in a subset of lung cancers (Fig. S1B),
suggesting that its up-regulation might benefit the cancer cells.
Indeed, transient FGF13 knockdown reduced the clonogenicity
of H460 cells (Fig. 2A). Remarkably, FGF13-silenced cells dis-
played a substantial increase in the sub-G1 population, detected
by flow cytometry (Fig. 2B), and in poly(ADP ribose)polymerase
(PARP) cleavage (Fig. 2C), indicative of apoptosis. A similar
effect was observed in another FGF13-high NSCLC cell line,
H1437 (Fig. S2A). Of note, FGF13 silencing did not affect miR-
504 expression significantly (Fig. S2B).
Augmented apoptosis also was elicited by siRNA specifically
targeting the FGF13 1A isoform (Fig. 2D). FGF13 knockdown-
induced apoptosis was attenuated by the pan-caspase inhibitor
z-VAD-FMK (Fig. S2C), confirming that it was at least partially
caspase-dependent. In contrast, p53 depletion did not attenuate
FGF13 knockdown-induced apoptosis (Fig. S2D), implying that
p53 is not required for this death. Rather, p53 depletion
appeared to augment cell death even further, although the effect
did not reach statistical significance (Fig. S2D).
Fig. 2. FGF13 depletion induces apoptosis and up-
regulates ROS in H460 cells. (A) Representative clo-
nogenic assay of H460 cells transfected with FGF13
siRNA (siFGF13) or control siRNA (siC) for 6 h and
then seeded in triplicate at equal cell density in six-
well plates. Colonies were stained with crystal violet
and scanned (Upper) and were quantified (Lower) as
described in SI Materials and Methods. **P < 0.01.
(B) Representative image of FACS-assisted analysis of
the DNA content of cells transfected with FGF13
siRNA (siFGF13) or control siRNA (siC) for 48 h. The
percentage of cells with sub-G1 DNA content is in-
dicated. (C) Western blot analysis with antibodies to
the indicated proteins 48 h after transient trans-
fection of H460 cells with FGF13 (FGF13) or control
(C) siRNA. Cl. PARP, cleaved PARP. GAPDH served as
loading control. (D, Top) Percentage of cells with
sub-G1 DNA content based on FACS analysis of H460
cells transiently transfected for 48 h with FGF13
siRNA (FGF13), control siRNA (C), or siRNA specific for
the FGF13 1A isoform (F1A). Data are expressed as
fold change and represent the means ± SD from
three independent experiments. ***P < 0.001, *P <
0.05 versus control siRNA. (Middle) Lysates of cells
transfected as above were subjected to Western blot
analysis with the indicated antibodies. (Bottom)
qPCR analysis of FGF13 mRNA normalized to GAPDH
to monitor FGF13 knockdown in the above experi-
ment. qPCR was performed with primers specific for
the 1A isoform (F1A) or common to all isoforms
(FGF13). (E, Upper) Cells treated as in C were stained
with the fluorescent dye H2DCFDA to measure ROS
levels by FACS analysis. (Lower) Relative H2DCFDA
fluorescence; data are expressed as the means ± SD
from three independent experiments. ***P < 0.001.
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Additionally, phosphorylated p38 and phosphorylated histone
2A variant H2AX (γ-H2AX) were elevated (Fig. 2C), indicative of
stress and DNA damage, respectively.
Notably, FGF13 silencing increased cellular ROS (Fig. 2E)
24 h after siRNA transfection (Fig. S2E). The free radical
scavenger N-acetylcysteine (NAC) provided a modest but signifi-
cant rescue from apoptosis (Fig. S2F), suggesting that increased
ROS is partly responsible for cell death upon FGF13 down-
regulation. Remarkably, comparable ROS up-regulation also
was elicited by p53 silencing (Fig. S2G). Hence, both FGF13
and p53 restrict ROS production in these cells.
Overall, these findings suggest that elevated FGF13 supports
homeostasis in lung cancer cells, mitigating oxidative stress and
promoting survival.
Fig. 3. Binding partners and nucleolar localization of FGF13. (A) Heat map of the spectral counts of FGF13-interacting proteins identified by mass
spectrometry in U2OS cells stably expressing Flag-FGF13 1A. See SI Materials and Methods. ***P < 0.001, **P < 0.01, *P < 0.05 versus U2OS cells stably
transfected with empty vector. (B) U2OS cells stably expressing Flag-FGF13 1A or empty vector were subjected to IP with anti-Flag antibodies followed by
Western blot analysis with antibodies specific for Flag, B23/nucleophosmin (NPM1), NCL, or RPL11 (L11). (C ) Cells were subjected to IP as in B, except that
bound proteins were eluted from the anti-Flag beads with excess Flag epitope peptide and then were subjected to Western blot analysis with antibodies
specific for Flag or UBF. (D) Nucleoli were isolated from U2OS cells stably expressing Flag-FGF13 1A or empty vector. Nucleolar extracts were subjected to
IP with anti-Flag antibodies, followed by Western blot analysis with the indicated antibodies. (E ) U2OS cells stably expressing Flag-FGF13 1A were
subjected to immunofluorescence staining with anti-Flag (to visualize FGF13 1A) (Left) or anti-B23/nucleophosmin (NPM1) (Upper Center), or anti-UBF
(Lower Center) antibodies. (Right) Merged images in which yellow represents regions of colocalization. (Scale bars, 5 μm.) (F ) As in E, cells were either
treated (+) or not treated (−) with CSK buffer (SI Materials and Methods) and were stained with antibodies against Flag or nucleolin (NCL). Nuclear DNA
was stained with DAPI (blue). (Scale bars, 50 μm.) (G) H460 cells were transfected with FGF13 siRNA (siFGF13) or control siRNA (siC). Forty-eight hours later,
cells were subjected to IP with an antibody against nucleolin (NCL) or anti-HA as control, followed by Western blot analysis with the indicated antibodies.
RPL11 (L11), a known NCL interactor, served as positive control. GAPDH served as loading control. Short (S) and long (L) exposures of FGF13 are shown. (H)
H460 cells were fractionated into cytosolic (C), nuclear (N), and nucleolar (Nu) fractions, followed by Western blot analysis with the indicated antibodies.
Tubulin, lamin B, and fibrillarin served as markers for the cytosolic, nuclear, and nucleolar fractions, respectively. (I) H460 cells were extracted with CSK
buffer as in F and were subjected to immunofluorescence staining with antibodies against FGF13 (green) (Upper Right) or nucleolin (NCL, red) (Lower
Right) along with DAPI (blue) (Upper Left) for DNA. (Lower Left) A merged image of all three stains. (Scale bar, 50 μm.)
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FGF13 1A Is a Nucleolar Protein. Although FGF13 1B binding part-
ners have been described (24, 25), the FGF13 1A interactome
remained unexplored. Therefore, U2OS cells expressing low levels
of FGF13 were stably transduced with Flag-FGF13 1A, which then
was immunoprecipitated and subjected to mass spectrometry anal-
ysis to identify putative interactors. Interestingly, these were highly
enriched for nucleolar proteins, including nucleolin, B23/nucleo-
phosmin (NPM1), and numerous ribosomal proteins (Fig. 3A),
suggesting, in agreement with an earlier report (15), that FGF13
1A resides mainly in the nucleolus. Coimmunoprecipitation
analysis confirmed the association of Flag-FGF13 1A with several
endogenous nucleolar proteins, including ribosomal protein L11
(RPL11) (Fig. 3B) and the transcription factor upstream binding
factor (UBF) (Fig. 3C), a positive regulator of rRNA synthesis.
Subcellular fractionation confirmed binding of Flag-FGF13 to
NPM1, nucleolin, and RPL11 in the nucleolar fraction, demon-
strated by immunoprecipitation (IP) with Flag (Fig. 3D), NPM1
(Fig. S3A), or nucleolin (Fig. S3B) antibodies.
Indeed, immunofluorescence staining revealed predominantly
nucleolar Flag-FGF13 1A localization (Fig. 3E), with a weak
nucleoplasmic signal. Flag-FGF13 1A colocalized closely with
UBF in the fibrillar center and the dense fibrillar component
(Fig. 3E, Lower); partial overlap with NPM1 in the granular
component was observed also (Fig. 3E, Upper).
Prediction of nucleolar localization sequences (NoLS) (26, 27)
suggested that FGF13 1A contains such elements near its N ter-
minus (Fig. S3C), a region absent in FGF13 isoforms reported to be
cytoplasmic (15). Furthermore, upon actinomycin D-mediated in-
hibition of rRNA synthesis, FGF13 1A redistributed to the nucle-
oplasm (Fig. S3D), like other nucleolar proteins (28). Notably,
removal of soluble cytoplasmic and nuclear proteins through de-
tergent extraction [CytoSKeleton (CSK)] before fixation confirmed
the tight nucleolar association of Flag-FGF13, similar to that of
nucleolin (Fig. 3F). IP analysis validated a specific interaction of
endogenous FGF13 with nucleolin (Fig. 3G, compare lane 3 with
lane 5), and cell fractionation corroborated its nucleolar distribu-
tion (Fig. 3H). Importantly, endogenous FGF13 remained associ-
ated with the nucleolar compartment after detergent extraction
(Fig. 3I). Thus, FGF13 1A is a bona fide nucleolar protein.
FGF13 Depletion Augments Nucleolar Size and Increases rRNA and
Protein Synthesis. FGF13 silencing led to a significant increase
in average nucleolar size, revealed by fibrillarin, UBF, and NPM1
staining (Fig. 4 A and B; quantification in Fig. 4 C and D). The
total number of nucleoli per cell was unaffected (Fig. S3E).
The nucleolus is the site of ribosomal biogenesis, including
transcription and processing of rRNA. Nucleolar enlargement is
often associated with increased rRNA content (29). We therefore
assessed the impact of FGF13 down-regulation on rRNA synthesis
by quantifying 47S precursor rRNA (pre-rRNA). Remarkably,
FGF13 knockdown strongly up-regulated 47S pre-rRNA (Fig. 4E).
The effect was most prominent 24 h after transfection and was at-
tenuated at 48 h (Fig. 4F), probably reflecting adaptation through a
negative feedback loop or merely that the cells were gradually un-
dergoing stress-induced apoptosis. In either case, these results imply
that elevated FGF13 restricts rRNA synthesis in these cancer cells.
Augmented rRNA production is usually coupled with increased
protein synthesis. Therefore we assessed protein synthesis rates,
using the puromycin analog O-propargyl-puromycin (OPP), which
is incorporated into newly translated polypeptides and can be
fluorescently labeled. Indeed, FGF13 depletion augmented pro-
tein synthesis (Fig. 5 A and C), and this augmented synthesis was
abolished by the protein synthesis inhibitor cycloheximide (CHX).
Quantification of fluorescence intensity by microscopy (Fig. 5B)
and by FACS (Fig. 5D) confirmed the increase in newly translated
polypeptides. Notably, the effect was more modest than the
corresponding increase in rRNA synthesis. FGF13-depleted cells
also displayed enhanced mTOR activity, evident by increased
phosphorylation of S6 kinase, RPS6, and 4EBP1 (Fig. 5E).
Next, we performed RNA sequencing (RNA-seq) analysis on
H460 cells without and with FGF13 knockdown (Table S1). Gene
Ontology (GO) enrichment analysis (Table S2) revealed that
FGF13 depletion induced processes associated with disrupted
protein homeostasis (proteostasis), including the unfolded protein
response (UPR) and the heat-shock response (HSR) (Fig. 5F).
Concomitantly, FGF13 depletion led to the accumulation of
CCAAT-enhancer–binding protein homologous protein (CHOP)
and spliced x-box binding protein-1 (sXBP1) mRNA (Fig. S4),
indicative of an endoplasmic reticulum (ER) stress response.
Exposure to the proteasome inhibitor MG132 augments the
accumulation of aberrant proteins and activates the HSR (30).
We reasoned that combining MG132 with FGF13 knockdown
might further exacerbate proteostasis stress. Indeed, combined
treatment resulted in augmented HSR, exemplified by up-regu-
lation of heat-shock protein A6 (HSPA6) mRNA (Fig. 5G)
encoding the heat-shock 70-kD protein (HSP70) family member
HSP70B′, which localizes to the nucleolus upon heat shock (31).
Together, these observations imply that elevated FGF13 can
protect cancer cells against proteostasis stress, probably by tun-
ing down protein synthesis and thereby avoiding excessive
emergence of aberrant polypeptides.
FGF13 Is Up-Regulated During Neoplastic Transformation to Promote
Transformed Cell Survival. To explore further links between
FGF13 up-regulation and cancer, we used an in vitro progression
series comprising slow-growing telomerase-immortalized WI-38
human lung embryonic fibroblasts (WI-38Slow), their fast-growing
derivatives obtained through extended passaging in culture
(WI-38Fast) (32, 33), and WI-38Fast cells transduced with activated
mutant H-RasV12 and selected for escape from p53-mediated
antiproliferative checkpoints, giving rise to stably transformed cells
(escapers, WI-38Ras) (34).
Remarkably, although FGF13 expression was almost un-
detectable in parental WI-38Slow cells, it became up-regulated in
WI-38Fast cells and further increased greatly in the WI-38Ras
escapers (Fig. 6A). miR-504 followed the same trend (Fig. 6B),
suggesting positive selection for elevated expression of the
FGF13 locus during transformation. In further support of se-
lection, rather than direct up-regulation, transient over-
expression of H-RasV12 in WI-38Fast cells did not increase
FGF13 mRNA (Fig. S5A). Actually, oncogenic Ras was reported
to repress FGF13 expression in other cells (35). To investigate
the dynamics of this process, WI-38Fast cells were transduced
with H-RasV12. As seen in Fig. S5B, FGF13 mRNA started rising
only ∼10 d after H-RasV12 transduction. The gradual increase in
FGF13 mRNA might be facilitated by epigenetic attenuation of
p53 activity during establishment of the escaper population (34).
WI-38Ras cells display elevated ROS, relative to their WI-38Fast
progenitors (Fig. 6C), probably because of constitutive Ras acti-
vation (36). FGF13 1A knockdown elicited a very slight increase in
ROS in WI-38Fast but a significant increase in WI-38Ras cells (Fig.
6D). Concomitantly, FGF13 1A-silenced WI-38Ras cells displayed
elevated phospho-p38 and cleaved PARP and a marked increase in
the sub-G1 subpopulation (Fig. 6E), indicative of exacerbated
stress-induced apoptosis. Of note, silencing all FGF13 isoforms
together did not exert a stronger effect than silencing FGF13 1A
alone (Fig. S5 C and D). As expected, FGF13 siRNA did not affect
the viability of WI-38slow cells (Fig. S5E), which hardly express
FGF13 mRNA. In agreement with its effects on ROS and apo-
ptosis, FGF13 1A depletion reduced the clonogenicity of WI-38Ras
cells more than that of WI-38Fast cells (Fig. 6 F and G). Thus, WI-
38 cells accrue a gradual increase in FGF13 expression as they
progress along the transformation axis and become increasingly
“addicted” to FGF13 overexpression as a survival mechanism.
To address the impact of FGF13 up-regulation during Ras-induced
transformation more directly, WI-38Fast cells were transduced with
H-RasV12, either alone or in combination with FGF13 1A. Acute
H-RasV12 overexpression led to a substantial reduction in cell number
(Fig. 6H, Upper), in association with increased cell death as assessed
by propidium iodide uptake (Fig. S5F). Notably, WI-38Fast cells have
silenced p16 and p14ARF expression (32) and tend to undergo
apoptosis, rather than senescence, upon Ras hyperactivation (34).
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Concomitantly, RasV12 decreased the clonogenic survival of WI-
38Fast cells (Fig. 6H). Thus, FGF13 1A overexpression reduced
H-RasV12–induced cell death, mitigated the decrease in cell
number, restored the clonogenic capacity of H-RasV12–infected
cells, and enabled the retention of higher mutant Ras expression
(Fig. S5G).
Hence, although FGF13 1A expression is not directly modu-
lated by activated Ras, it is gradually up-regulated during stabi-
lization of the transformation process, enabling mutant Ras-
expressing cells to cope better with oncogene-induced stress.
Discussion
miR-504 is a negative regulator of p53, directly targeting p53
mRNA and quenching p53 levels and activity (4). In agreement
with a putative oncogenic role, miR-504 is overexpressed in a va-
riety of cancers (4, 37–40). However, relatively little is known about
the mechanisms that control miR-504 expression, beyond its down-
regulation by the secreted factors CTGF and TFF1 (38, 39). We
now show that miR-504, along with its host gene FGF13, is subject
to constitutive transcriptional repression by p53. This finding is
consistent with an earlier study, in which MMTV–Wnt–induced
mouse mammary tumors emerging on a p53+/− background were
observed to produce more miR-504 than tumors developing in
p53+/+ mice (41). The p53–miR-504 negative feedback loop adds a
module to the p53 network, possibly acting to boost p53 protein
levels further in response to p53-activating signals.
Notably, FGF13-mediated regulation of cell survival does not
require WT p53, as observed in H1437 cells harboring mutant
p53 (R267P) or upon p53 down-regulation in WT p53 H460
cells. This observation is particularly relevant given the high
prevalence of TP53 mutations in NSCLC (42).
Our study reveals an additional important activity of FGF13.
We show that FGF13 1A resides primarily in the cell nucleolus,
where it represses rRNA synthesis. Notably, FGF13 1A interacts
with UBF, a key mediator of rRNA transcription, suggesting that
FGF13 1A may directly inhibit UBF and thereby compromise the
ability of RNA polymerase I (Pol I) to transcribe the rDNA genes.
In addition, FGF13 may affect RNA Pol I activity by binding
nucleolin, whose interaction with RNA Pol I is required for RNA
Pol I-mediated transcription (43). Although our study highlights
the impact of FGF13 1A, possible contributions of other FGF13
isoforms should not be disregarded. Indeed, some FGF13 iso-
forms have been associated with cisplatinum resistance (44).
Moreover, in neurons, FGF13 1B regulates microtubule dynamics
and facilitates cell migration (24). Hence, the loss of p53 function
also may promote cancer by up-regulating other FGF13 isoforms.
FGF13 is overexpressed in several types of cancer, including
pancreatic endocrine carcinoma (17), melanoma (16), multiple
myeloma (45), and lung cancer (this study). FGF13 overexpression
might have suggested that FGF13 plays an oncogenic role, a
notion seemingly consistent with the repression of its expression
by p53. However, we demonstrate here that FGF13 inhibits
rRNA and global protein synthesis, as reported for canonical
tumor suppressors such as p53 and Arf (46, 47). Conversely,
many oncogenes promote ribosomal biogenesis and protein
synthesis to facilitate cell growth and proliferation.
So how does one rationalize FGF13 overexpression in cancer?
Our study implies that FGF13 up-regulation is not required to drive
Fig. 4. FGF13 depletion augments nucleolar size and increases ribosomal RNA synthesis. (A and B) H460 cells were transiently transfected with FGF13 siRNA
(siFGF13) or control siRNA (siC) and 24 h later were subjected to immunofluorescence staining with antibodies against the nucleolar proteins fibrillarin (FBL,
red), UBF (green) (A), and B23/nucleophosmin (NPM1) (green) (B). (Scale bar, 5 μm.) (C and D) Quantification of nucleolar diameter performed on cells stained
with an anti-UBF (C) or anti-NPM1 (D) antibody 24 or 48 h after transfection as in A and B (SI Materials and Methods). Data are shown as means ± SD from 15
cells per condition, from two independent experiments. ***P < 0.001. (E and F) H460 cells were transfected as in A and B, and RNA was extracted 24 (E) or 48
(F) h after transfection and subjected to qPCR analysis of 47S pre-rRNA and FGF13 mRNA, normalized to GAPDH. Data are expressed as mean ± SD from three
independent experiments. **P < 0.01, *P < 0.05.
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cancer but rather helps the emerging cancer cells to cope with the
unwelcome consequences of oncogene activation. Specifically, many
oncogenes, as exemplified by c-Myc, BRAF, and Ras, elicit a sub-
stantial increase in the rate of protein synthesis; although facilitating
cell proliferation, this increased synthesis also overburdens the
cellular protein quality control mechanisms, eventually giving rise to
ER stress and proteotoxic stress (48–50). Furthermore, mutations in
protein-coding regions, frequent in cancer, also increase the load of
aberrant proteins and the risk of proteotoxic stress; in that regard, it
is remarkable that FGF13 overexpression is observed in lung cancer
and melanoma, two cancer types harboring extensive somatic
mutations. The challenge to proteostasis in tumor cells may be
exacerbated further by the presence of DNA duplications, deletions,
and copy number variations, causing imbalance in the stoichiometry
of multisubunit complexes (51). We propose that FGF13 up-regu-
lation dampens this proteostasis stress by tuning down the rate of
protein synthesis, eventually bringing it to a level that represents a
compromise between the need to produce more proteins and the
ability of the cancer cell to evade lethal proteotoxic stress. Indeed,
translational attenuation can improve translation fidelity, allowing
proper folding of newly synthesized peptides and reducing the load
on the protein quality control machinery (52).
Furthermore, perturbed proteostasis produces ROS that
eventually might trigger apoptosis (53). By moderating the
Fig. 5. FGF13 down-regulation augments protein synthesis and induces unfolded protein stress. (A) Fluorescence microscopy imaging of protein synthesis in
H460 cells transiently transfected with control siRNA (siC) or FGF13 siRNA (siFGF13) for 36 h. Fluorescence staining of nascent polypeptides was done with OPP
using Alexa 568-azide (red) along with DAPI (blue) as described in SI Materials and Methods. Where indicated, CHX (100 μg/mL) was added to block protein
synthesis. (Scale bar, 20 μm.) (B) Box plot quantification of Alexa Fluor 568 fluorescence intensity based on 8–10 fields containing ∼1,500 cells per condition,
derived from two biological replicates. ***P < 0.001. (C) Representative FACS analysis of Alexa Fluor 568-azide fluorescence performed on cells treated as in A.
(D) Quantification of FACS analysis done as in C. Data are expressed as fold change in Alexa Fluor 568 mean fluorescence intensity ± SD from two independent
experiments. (E) Western blot analysis with antibodies to the indicated proteins 48 h after transient transfection of H460 cells with FGF13 siRNA (siFGF13) or
control siRNA (siC). GAPDH served as loading control. (F) GO enrichment analysis of RNA-seq data performed on H460 cells transiently transfected with FGF13
or control siRNAs. GO terms belonging to biological processes were sorted by P values. (G) RNA was isolated from cells transfected as in E and treated or not with
50 μM MG132 (MG) for 4 h. HSPA6 mRNA was quantified by qPCR and normalized to GAPDH. Data are shown as the mean ± SD of three independent ex-
periments. **P < 0.01, *P < 0.05.
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increase in protein synthesis and quenching ROS accumulation,
FGF13 might support cancer cell survival without compromis-
ing the other cancer-promoting effects of activated oncogenes.
Of note, FGF13 is also overexpressed in cell lines derived from
multiple myeloma (45), a malignancy characterized by persis-
tent proteostasis stress and highly reliant on mechanisms that
cope with such stress (54).
It is also conceivable that different components of the protein
synthesis machinery, whose levels are tightly coordinated in normal
cells, become differentially deregulated upon oncogenic activation,
creating a chronic imbalance. Of note, excessive accumulation
of nascent rRNA can directly cause DNA damage by forming
rRNA:rDNA hybrids (55). Thus, the incipient cancer cell may
remedy an imbalance between different components of the protein
Fig. 6. FGF13 is up-regulated in an in vitro model of cellular transformation and supports the survival of cells overexpressing oncogenic Ras. (A and B) Cells from a
tissue-culture model of neoplastic transformation, comprising immortalized slow-growing WI-38 fibroblasts (WI-38Slow), their rapidly growing derivatives
(WI-38Fast), and WI-38Fast cells transformed with a retrovirus encoding mutant H-Ras and selected for escape from Ras-induced antiproliferative checkpoints
(WI-38Ras), were subjected to qPCR quantification of FGF13mRNA (A) ormiR-504 (B). Values were normalized to GAPDH or SNORD44, respectively *P < 0.05, **P <
0.01, ***P < 0.001. (C) WI-38Fast and WI-38Ras cells were stained with H2DCFDA, and ROS levels were determined by FACS. Fluorescence intensity is expressed as
fold change. Data are shown as mean ± SD from three independent experiments. *P < 0.05. (D, Left and Center) Representative FACS images of WI-38Fast (Left)
and WI-38Ras (Center) cells transiently transfected with FGF13 1A-specific siRNA (siF1A) or control siRNA (siC) for 48 h and stained for ROS as in C. (Right)
Quantification of H2DCFDA fluorescence intensity expressed as fold change. Data are expressed as mean ± SD from three independent experiments. *P < 0.05; ns,
not significant. (E, Left) Quantification of the relative proportion of cells with sub-G1 DNA content, deduced from FACS analysis of WI-38Fast and WI-38Ras 72 h
after transfection with FGF13 1A-specific siRNA (siF1A) or control siRNA (siC). Data are expressed as fold change of FGF13 1A-specific siRNA relative to the control
siRNA of each population. (Right) Western blot analysis of representative lysates probed with the indicated antibodies. GAPDH served as loading control. ***P <
0.001; ns, not significant. (F and G, Upper) Representative images of WI-38Fast (F) and WI-38Ras (G) cells transfected with FGF13 1A-specific siRNA (siF1A) or control
siRNA (siC) for 6 h and subjected to clonogenic assay as in Fig. 2A. (Lower) Quantification results in upper panels. **P < 0.01. (H, Top) Representative images of
WI-38Fast cells infected with empty vector retrovirus (EV) or a retrovirus expressing H-RasV12 (Ras), either alone or together with a retrovirus expressing FGF13 1A
(FGF13+Ras). Hygromycin selection was initiated 2 d after infection and was continued for 8 d. Cultures were photographed 14 d after infection through a 4× phase-
contrast objective. (Scale bars, 500 μm.) (Middle) Representative picture of a clonogenic assay of WI-38Fast cells infected as described above. After 8 d of drug selection
cells were seeded in triplicate at an equal cell density in six-well plates and were maintained without drug for an additional 11 d. (Bottom) Colonies then were stained
with crystal violet, scanned, and quantified as described in SI Materials and Methods. ***P < 0.001.
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biosynthetic machinery by selectively tuning down the component
that is most aberrantly up-regulated. We propose that when that
component is rRNA transcription, remedy can be achieved by
increasing FGF13, thereby putting an adjustable brake on
rRNA synthesis. This effect is reminiscent of RUNX1 muta-
tions in myelodysplastic syndrome, which reduce rRNA syn-
thesis and ribosomal biogenesis, tune down p53 levels, and render
hematopoietic stem cells more resilient to stress-induced apo-
ptosis (56). Interestingly, the PHF6 protein, which, like FGF13,
interacts with UBF and represses rRNA synthesis (55), is
overexpressed in B-cell lymphoma and has been suggested to
play a role in progression of this malignancy (57), often driven
by c-Myc hyperactivation.
As shown here, stepwise transformation is accompanied by
progressive up-regulation of FGF13, along with increased de-
pendence on FGF13 for buffering excessive ROS and for sur-
vival. Introduction of oncogenic Ras into WI-38Fast cells triggers
extensive apoptosis and senescence; only a minor fraction of the
cells escape these failsafe checkpoints, eventually giving rise to
stably transformed progeny (34). Our data suggest that FGF13
up-regulation is selected for during this stabilization period,
because it enables the cancer cells to cope more effectively with
the chronic proteostasis stress imposed by Ras activation. In the
course of this process, the transformed cells might become
addicted to high levels of FGF13, as indicated by their pro-
pensity to undergo apoptosis upon FGF13 depletion.
In nontransformed cells, negative regulation of FGF13 by p53
may serve to ensure the robustness of protein homeostasis.
Transient attenuation of p53 activity, which may be desirable
under particular physiological conditions (e.g., early embryonic
development, wound healing), might endanger the cell by
allowing excessive ROS accumulation (58) (see also Fig. S2E).
Concurrent transient up-regulation of FGF13 resulting from
attenuated p53 activity may help avert these undesirable con-
sequences by providing an alternative layer of protection. This
concerted action is made even more effective by the simulta-
neous up-regulation of miR-504, which reinforces the quenching
of p53 activity. Importantly, we surmise that in normal cells this
circuit is dynamically regulated, temporally and spatially, as-
suring its transient nature. However, cancer cells that retain WT
p53 might co-opt this mechanism and fix it in an “on” state,
thereby blunting p53 by the excessive miR-504 and simulta-
neously gaining FGF13-mediated protection against potential
proteostasis stress imposed by oncogenic events. Such cells will
be more likely to possess a long-term competitive advantage.
In sum, although FGF13 is highly unlikely to play a role in driving
cancer, our findings suggest that it nevertheless is a facilitator of
cancer progression. In fact, FGF13 may be viewed as an enabler,
enabling the emerging tumor cells to cope with the stressful impact
of cancer-associated deregulation of key cellular processes. Such
enablers allow the cancer cell to reset its metabolic balance and
achieve higher biosynthetic rates without going overboard. Con-
comitantly, these cells acquire an addiction to the enabler, as shown
for other buffering proteins such as molecular chaperones (21, 59),
thus positioning such enablers as potential targets for cancer therapy.
Materials and Methods
Cell Culture and Chemicals. All cell lines used in this study were grown and
maintained as described in SI Materials and Methods.
Transfections and Infections. siRNA transfections were performed with Dhar-
mafect 1 reagent (Dharmacon) according to themanufacturer’s protocol. siRNAs
for FGF13 and p53 were purchased as SMARTpools, and FGF13 1A was pur-
chased as a single oligo (GGCAAGACCAGCUGCGACAUU) from Dharmacon. All
siRNA oligos were used at a final concentration of 20 nM except for double-
knockdown assays in which 10 nM of each siRNA was used.
Retroviral infection of WI-38Fast cells was performed as previously de-
scribed (34). Hygromycin selection was initiated 48 h after infection.
Flow Cytometry. Cell-cycle analysis and measurement of endogenous cellular
ROS were performed with propidium iodide staining or with the ROS-sen-
sitive dye 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) (Molecular
Probes), respectively, as described in SI Materials and Methods.
Clonogenic Assay. Six hours after transfection with siRNAs, cells were
trypsinized and reseeded in six-well plates at a density of 3,000 cells per
well and then were grown until colonies were visible. For infections, 8 days
after drug selection the cells were trypsinized and reseeded in six-well
plates at a density of 5,000 cells per well. Staining of colonies and analysis
are described in SI Materials and Methods.
IP. For Flag-FGF13 IP, U2OS cells were harvested, washed with ice-cold PBS,
and lysed on ice in NET lysis buffer [50 mM Tris·HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA 0.1% Nonidet P-40] supplemented with protease inhibitor mix
(Sigma) and phosphatase inhibitor mixture II and III (Sigma). Cells were
sonicated in a Bioruptor sonicator (Diagenode), 30 s on and 60 s off for a
total of 10 min, and then were centrifuged at 14,000 × g for 10 min at 4 °C.
After preclearing, lysates were incubated at 4 °C for 2–4 h with anti-Flag
antibodies covalently attached to beads (Sigma). A 1/20 aliquot of the
cleared suspension was taken as input. Next, the beads were washed three
times with NET buffer, and elution was carried out using a Flag peptide
(Sigma) in PBS when indicated. Samples were resolved by SDS/PAGE fol-
lowed by Western blotting. Nucleolin IP was performed with anti-nucle-
olin antibody (Abcam) plus protein A-Sepharose beads (Repligen).
Western Blot Analysis. Immunoblot analysis was performed as previously
described (60). The list of antibodies used is provided in SI Materials
and Methods.
Isolation of Total RNA and qPCR. RNA isolation, RT-PCR and qPCR analysis are
described in SI Materials and Methods. Primer sequences are detailed in SI
Materials and Methods.
Immunofluorescence Staining.Nucleolar proteins were visualized as previously
reported (61) and described in SI Materials and Methods.
Cell Fractionation. Cytoplasm, nuclei, and nucleoli were prepared from 10 ×
106 H460 cells essentially as previously reported (62) and as described in SI
Materials and Methods.
Measurement of Nucleolar Diameter. The average diameter of the nucleolus
was measured in H460 cells stained by indirect immunofluorescence with
antibodies against nucleolar proteins UBF or NPM1 using Zeiss LSM700
confocal laser scanning microscopy and analyzed with ZEN imaging software
(Carl Zeiss).
Measurement of Protein Synthesis. Newly translated polypeptides were ana-
lyzed by using the puromycin analog OPP (Jena Bioscience) with further fluo-
rescent labeling and were quantified by microscopy and by FACS as described in
SI Materials and Methods.
Database Analysis. Lung adenocarcinoma data were generated by the TCGA
Research Network (https://cancergenome.nih.gov/) and were downloaded
from TCGA data portal. Outliers were eliminated from box plots.
Mass Spectrometry Analysis. The detailed procedure of sample preparation
and a description of data processing, searching, and analysis are provided in SI
Materials and Methods.
RNA-Seq. Library construction, sequencing, and GO enrichment analysis are
described in SI Materials and Methods.
Statistical Analysis. Statistical significance was determined using a two-tailed
Student’s t test. Unless stated otherwise, the P value was calculated based on
three biological replicates.
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